SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+35.12%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$374M
AUM Growth
+$374M
(+7.5%)
Cap. Flow
-$20.9M
Cap. Flow
% of AUM
-5.59%
Top 10 Holdings %
Top 10 Hldgs %
57.86%
Holding
84
New
17
Increased
16
Reduced
11
Closed
27
Top Buys
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$17.3M |
| 2 |
AUTL
Autolus Therapeutics
AUTL
|
$16M |
| 3 |
Roivant Sciences
ROIV
|
$14.6M |
| 4 |
Immunovant
IMVT
|
$9.86M |
| 5 |
Cabaletta Bio
CABA
|
$9.44M |
Top Sells
| 1 |
Merus
MRUS
|
$12.1M |
| 2 |
Arcellx
ACLX
|
$12.1M |
| 3 |
Spyre Therapeutics
SYRE
|
$12M |
| 4 |
Protagonist Therapeutics
PTGX
|
$11.8M |
| 5 |
BridgeBio Pharma
BBIO
|
$10.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Roivant Sciences
ROIV
$8.15B
| $37.5M | 9.9% |
3,553,844
+1,384,728
| +64% | +$14.6M |
|
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $29M | 7.67% |
619,789
+370,214
| +148% | +$17.3M |
|
3
Syndax Pharmaceuticals
SNDX
$1.41B
| $26.2M | 6.93% |
1,100,988
+6,494
| +0.6% | +$155K |
|
4
Arcutis Biotherapeutics
ARQT
$1.86B
| $21.9M | 5.78% |
2,205,899
-388,637
| -15% | -$3.85M |
|
|
5
Immunovant
IMVT
$2.56B
| $20.3M | 5.36% |
627,228
+305,213
| +95% | +$9.86M |
|
|
AUTL
6
Autolus Therapeutics
AUTL
$399M
| $18.9M | 5% |
2,965,721
+2,514,346
| +557% | +$16M |
|
7
Amicus Therapeutics
FOLD
$2.34B
| $18.2M | 4.82% |
1,547,141
+684,326
| +79% | +$8.06M |
|
|
8
Cabaletta Bio
CABA
$133M
| $17.1M | 4.53% |
1,003,916
+553,210
| +123% | +$9.44M |
|
9
KalVista Pharmaceuticals
KALV
$678M
| $13.8M | 3.64% |
1,161,060
+737,886
| +174% | +$8.75M |
|
10
Applied Therapeutics
APLT
$71M
| $13.7M | 3.63% |
2,017,016
+1,109,864
| +122% | +$7.55M |
|
11
Eli Lilly
LLY
$657B
| $11.7M | 3.1% |
15,067
| – | – |
|
|
12
Merus
MRUS
$4.98B
| $10.5M | 2.78% |
233,871
-267,935
| -53% | -$12.1M |
|
|
13
Arcellx
ACLX
$3.85B
| $9.76M | 2.58% |
140,267
-173,337
| -55% | -$12.1M |
|
14
VistaGen Therapeutics
VTGN
$102M
| $9.29M | 2.46% |
1,848,582
+58,400
| +3% | +$294K |
|
15
Tarsus Pharmaceuticals
TARS
$2.47B
| $8.08M | 2.14% |
222,253
+191,263
| +617% | +$6.95M |
|
16
Pyxis Oncology
PYXS
$79.4M
| $7.64M | 2.02% |
+1,794,195
| New | +$7.64M |
|
17
Insmed
INSM
$28.8B
| $7.39M | 1.95% |
272,448
+98,869
| +57% | +$2.68M |
|
18
Tourmaline Bio
TRML
$601M
| $6.28M | 1.66% |
+274,219
| New | +$6.28M |
|
19
AnaptysBio
ANAB
$569M
| $6.07M | 1.6% |
269,548
+224,548
| +499% | +$5.06M |
|
20
Larimar Therapeutics
LRMR
$310M
| $5.62M | 1.49% |
740,877
-42,295
| -5% | -$321K |
|
21
Immatics
IMTX
$619M
| $5.17M | 1.37% |
491,926
-528,288
| -52% | -$5.55M |
|
22
Soleno Therapeutics
SLNO
$3.6B
| $4.96M | 1.31% |
+115,833
| New | +$4.96M |
|
|
SLRN
23
DELISTED
ACELYRIN
SLRN
| $4.82M | 1.28% |
714,773
+127,400
| +22% | +$860K |
|
24
Janux Therapeutics
JANX
$1.37B
| $4.58M | 1.21% |
+121,642
| New | +$4.58M |
|
25
Biohaven
BHVN
$1.63B
| $4.56M | 1.21% |
83,461
-27,893
| -25% | -$1.53M |
|